---

The FDA’s Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT) hosted a public webinar on Tuesday, November 16, 11:00 a.m.-12:00 p.m. ET.

The webinar brought together patients, caregivers, advocates, and other important stakeholders to discuss how the FDA is working to advance regenerative medicine and its role in ensuring regenerative medicine treatments, such as approved gene therapies, are safe and effective for patients. The webinar speakers included Wilson Bryan, MD, Director of OTAT, and Anne Rowzee, PhD, Associate Director of Policy for OTAT.

This webinar was the first in an educational webinar series called RegenMedEd: An FDA CBER OTAT Webinar Series on Regenerative Medicine.

About the RegenMedEd Webinar Series

Regenerative medicine therapies, such as cell and gene therapies, hold promise for transforming medicine and creating options for patients living with difficult, rare, and often incurable diseases. Several approved regenerative medicine products are currently available, and research into regenerative medicine therapies in the United States continues rapidly, with many new therapies under investigation advancing into clinical studies. The FDA plays a vital role in facilitating the development of regenerative medicine therapies, as well as in ensuring approved products are safe and effective for patients.

To further engage patients, caregivers, and advocates on the topic of regenerative medicine, OTAT is excited to present an educational webinar series called RegenMedEd: An FDA CBER OTAT Webinar Series on Regenerative Medicine. The RegenMedEd webinar series aims to bring together patients, caregivers, patient advocates, and FDA staff to discuss foundational information about regenerative medicine therapies, such as gene therapy and cell therapy, and explore opportunities for stakeholders to engage with the FDA to help advance drug development.

Recording

Zoom Webinar Recording for Regenerative Medicine 101 Webinar 

---